DA-7503 / Dong-A - LARVOL DELTA

K Pharmaceutical Bio, Alzheimer's disease largest conference 'AAIC' sortie... Aiming for 'Tau·BBB·AI diagnosis' [Google translation] (BioNews) - "Dong-A ST will present a poster for 'DA-7503 (development code name)' for the second consecutive year. DA-7503 is a small molecule tau aggregation inhibitor currently under development as a treatment for Alzheimer's disease and tauopathy. DA-7503 selectively acts on separated and modified tau, inhibiting oligomer formation and thereby inhibiting intracellular tau accumulation. Following last year, preclinical data on DA-7503 related to Alzheimer's disease and tauopathy will be released this year as well."

Preclinical • Alzheimer's Disease • Tauopathies And Synucleinopathies

Drug Development. (PubMed, Alzheimers Dement) - "DA-7503 restores the impairments of memory and recognition, and ameliorates the aggregation and hyperphosphorylation of tau in transgenic mouse models of AD and other tauopathies. The inverse correlation between total Tau in CSF and DA-7503 exposure in plasma suggests that DA-7503 induces an increase of tau clearance from the brain and CSF tau may be explored as a biomarker in clinical development of DA-7503. Our findings indicate DA-7503 is a promising agent for the treatment of AD and primary tauopathies."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF T-tau

DA-7503, a novel tau aggregation inhibitor, ameliorates tau pathology and reduces CSF tau in transgenic mouse models of Alzheimer’s disease and primary tauopathies (AAIC 2024) - "DA-7503 restores the impairments of memory and recognition, and ameliorates the aggregation and hyperphosphorylation of tau in transgenic mouse models of AD and other tauopathies. The inverse correlation between total Tau in CSF and DA-7503 exposure in plasma suggests that DA-7503 induces an increase of tau clearance from the brain and CSF tau may be explored as a biomarker in clinical development of DA-7503. Our findings indicate DA-7503 is a promising agent for the treatment of AD and primary tauopathies."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF T-tau

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Dong-A ST Co., Ltd.

New P1 trial